Indexing in SciSearch means that articles published in the journal are systematically cataloged, with structured metadata including author names, affiliations, abstracts, and cited references. This infrastructure allows the journal’s output to be discovered through standardized searches, tracked for citation activity, and aggregated into bibliometric analyses. For authors, inclusion in the database ensures that their work is counted in institutional assessments and that citations to their papers are captured in the citation indexes that underpin modern research evaluation.

Alongside the indexing achievement, the journal recorded an Impact Factor of 5.5 in 2022, according to the source announcement. Within the Journal Citation Reports category of Pharmacology and Pharmacy, that figure corresponded to a Q1 quartile ranking, placing the journal 48th out of 278 titles in the category. Quartile rankings divide journals in a category into four groups by citation performance, and Q1 designates the top quarter, a status widely regarded as an indicator of strong relative influence within a field.

The Impact Factor itself is calculated from citations accrued in a given year to items published in the two preceding years, divided by the number of citable items published in that window. A score of 5.5 indicates that, on average, recent articles in the journal were cited more than five times within the measurement period. While bibliometricians caution that the metric reflects aggregate citation behavior rather than the quality of any individual paper, it remains one of the most consulted indicators when researchers choose where to submit manuscripts and when libraries decide which subscriptions to maintain.

For a journal focused on pharmaceutical investigation, the Q1 position in Pharmacology and Pharmacy carries particular weight. The category is crowded and competitive, spanning basic pharmacology, clinical pharmacy practice, drug delivery science, and regulatory science. Ranking 48th of 278 means the journal sits comfortably within the upper tier of a broad and active field, competing for attention with long-established titles that have decades of accumulated citation history.

The timing of the SciSearch indexing in 2021 is significant for the journal’s trajectory. Journals typically need a period of consistent publication and editorial rigor before they are evaluated for Web of Science coverage, and newly indexed titles generally receive their first Impact Factor only after a full citation window has elapsed. The 2022 Impact Factor therefore represents an early but meaningful validation of the journal’s growing footprint in the pharmaceutical sciences literature.

From the perspective of the research community, expanded indexing and strong citation metrics have practical consequences. Manuscript submissions tend to rise as visibility increases, which in turn allows editorial teams to be more selective. Authors in drug delivery, pharmacokinetics, and pharmaceutical formulation often weigh indexing status heavily because funding agencies and promotion committees in many countries explicitly require publications in Web of Science–indexed journals. The journal’s inclusion removes a barrier for authors in those systems and broadens its potential contributor base across Asia, Europe, and the Americas.

Librarians and information scientists also benefit from the development. Abstracting and indexing services create the connective tissue of scholarly communication: without them, discovering relevant articles across thousands of journals would be impractical. Coverage in SciSearch ensures that the journal’s content is integrated into discovery platforms used by universities and industry research groups, supporting systematic reviews, competitor intelligence in pharmaceutical R&D, and citation network analyses that map emerging research fronts in drug development.

The announcement, published through Springer’s journal updates for the Journal of Pharmaceutical Investigation, highlights how indexing and citation performance function as complementary signals. Indexing establishes that a journal meets baseline editorial and technical standards, while the Impact Factor and quartile ranking describe how its published work resonates with the research community. Together, they offer a concise summary of the journal’s standing: a title that has entered the mainstream of indexed pharmacology literature and, within two years, achieved a top-quartile citation profile in its category.

As the pharmaceutical sciences continue to expand, with growing attention to biologics, nanomedicine, and personalized drug delivery, the visibility provided by comprehensive indexing will shape which journals anchor the field’s scholarly record. For the Journal of Pharmaceutical Investigation, the 2021 SciSearch inclusion and the 2022 Impact Factor of 5.5, with its Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, mark a notable consolidation of its position among the publications that researchers in the discipline consult, cite, and trust.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, Web of Science, pharmaceutical sciences, journal citation metrics, Springer, scholarly publishing

Abstracting and indexing services form the backbone of modern scientific communication. When a journal is accepted into the Science Citation Index Expanded, it means that its published articles are systematically cataloged, metadata is extracted and standardized, and the content becomes discoverable through the Web of Science platform maintained by Clarivate. This process is far more than a bureaucratic formality. Inclusion in a major citation index determines whether researchers around the world can efficiently locate, retrieve, and cite a journal’s content. For pharmaceutical scientists, whose work often spans chemistry, pharmacology, formulation science, and clinical research, discoverability through trusted indexes is essential to ensuring that findings reach the practitioners and regulators who can act upon them.

The Science Citation Index Expanded, originally established as part of the Science Citation Index created by Eugene Garfield in the 1960s, has long served as one of the most selective and influential databases in academic publishing. Journals are admitted only after a rigorous evaluation process that examines editorial rigor, peer-review integrity, regularity of publication, international editorial diversity, and the citation behavior of the published literature. The fact that the Journal of Pharmaceutical Investigation entered SciSearch coverage in 2021 means that its articles published from that year onward are now tracked within the citation network that underpins modern bibliometrics, including the annual Journal Impact Factor calculations.

The Impact Factor itself remains the most widely recognized, and most widely debated, quantitative measure of a journal’s influence. Calculated each year by Clarivate, the metric reflects the average number of citations received in a given year by articles published in the journal during the two preceding years. An Impact Factor of 5.5 for 2022 indicates that, on average, articles published in the journal in 2020 and 2021 were cited 5.5 times in 2022 across the indexed literature. In the highly competitive Pharmacology and Pharmacy category, where hundreds of journals compete for the attention of a global research community, this average places the Journal of Pharmaceutical Investigation in the top tier of its discipline.

The quartile designation adds important context to the raw number. Ranking 48th among 278 journals in Pharmacology and Pharmacy corresponds to the Q1 band, the highest quartile of the category. Quartile rankings are derived by ordering all journals in a category by their Impact Factor and dividing the list into four equal groups. Q1 status is frequently used by research institutions, funding agencies, and university committees as a shorthand marker of journal prestige, influencing decisions about where researchers submit their work, how publications are weighted in hiring and promotion evaluations, and which journals libraries prioritize in their subscriptions. For authors weighing where to publish their pharmaceutical research, a Q1 designation with a 5.5 Impact Factor signals a venue with demonstrated reach and citation performance.

Pharmacology and pharmacy is one of the most densely populated categories in the Web of Science, reflecting the breadth of research that falls under its umbrella. The category encompasses basic pharmacological research into drug receptors and signaling pathways, medicinal chemistry and drug design, pharmacokinetics and drug metabolism, formulation and delivery technologies, clinical pharmacology, and pharmacy practice research. Journals in this space range from highly specialized outlets focused on narrow subfields to broad-spectrum publications that cover the full arc from molecule to medicine. Within this crowded landscape, achieving a position in the upper fifth of the category requires consistent publication of work that other researchers find useful enough to cite, year after year.

The Journal of Pharmaceutical Investigation has built its reputation on content that spans pharmaceutical technology, drug delivery systems, biopharmaceutics, and the clinical investigation of medicines. Its scope reflects the realities of contemporary drug development, where advances increasingly emerge at the boundaries between disciplines. Novel formulations such as lipid nanoparticles, long-acting injectables, and targeted delivery platforms demand expertise that bridges physical pharmacy, materials science, and regulatory science. Similarly, the evaluation of biosimilars, generics, and novel therapeutic modalities requires integration of analytical chemistry, pharmacokinetic modeling, and clinical trial methodology. A journal that serves as a conduit for this interdisciplinary work occupies a valuable position in the scientific ecosystem, and its citation performance suggests that the community recognizes that value.

Indexing in SciSearch also carries practical consequences for the researchers who publish in the journal. Articles included in the Science Citation Index Expanded are assigned digital object identifiers and standardized metadata that feed into institutional research information systems, national assessment exercises, and funder reporting requirements. In many countries, publication in indexed journals is a formal criterion for doctoral degree completion, grant eligibility, and academic advancement. For authors based in the Asia-Pacific region and beyond, where the Journal of Pharmaceutical Investigation has historically maintained strong connections through its publisher and editorial network, the journal’s expanded indexing profile enhances the portability and recognition of their published work across international evaluation systems.

The timing of the journal’s entry into the citation index is also noteworthy. Coverage beginning in 2021 means the journal’s recent publication record has been captured during a period of extraordinary activity in pharmaceutical research. The global pandemic accelerated investment in vaccine technology, antiviral therapeutics, and manufacturing science, while parallel advances in biologics, cell and gene therapies, and digital health technologies reshaped the drug development pipeline. Citation activity across pharmacology surged during this period, and journals positioned at the interface of pharmaceutical formulation and clinical investigation benefited from heightened attention to their subject matter. The 5.5 Impact Factor for 2022 reflects not only the journal’s editorial strategy but also the intensity of scientific exchange in its field during the measurement window.

Looking ahead, the combination of SciSearch indexing and Q1 standing positions the Journal of Pharmaceutical Investigation to attract submissions from a broader international author base and to deepen its role in shaping discourse on pharmaceutical innovation. Metrics are never a complete measure of a journal’s contribution, and the scholarly community continues to debate the appropriate weight given to Impact Factors in research assessment. Nevertheless, the journal’s current profile, indexed from 2021 with an Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, provides an objective snapshot of its standing. For a publication devoted to the investigation of medicines from laboratory bench to patient bedside, the numbers confirm what its readers and contributors have long understood: rigorous pharmaceutical science, when curated and disseminated effectively, earns its place at the center of the global research conversation.

Subject of Research: Indexing and citation metrics of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, abstracting and indexing, Clarivate, Web of Science, pharmaceutical sciences, journal metrics, drug development

To understand why indexing in Science Citation Index Expanded carries such weight, it helps to consider what the database actually represents. Maintained by Clarivate, the Science Citation Index Expanded is one of the core components of the Web of Science, the citation ecosystem that underpins the Journal Impact Factor, one of the most scrutinized metrics in academic publishing. Journals are not simply admitted to the index; they must pass through a rigorous evaluation process that examines editorial rigor, publishing timeliness, international diversity among authors and editors, citation behavior, and the overall scholarly contribution of the published work. Inclusion signals to researchers that a journal has met internationally recognized standards of quality and that its articles will be discoverable, citable, and counted in the citation networks that shape modern scientific communication.

The timing of the journal’s admission matters as well. Coverage beginning in 2021 means that articles published from that year onward are tracked in the index, allowing citations to accumulate and, after the standard waiting period, contributing to the Impact Factor calculations released annually. The 2022 Impact Factor of 5.5 reflects the frequency with which articles published in 2020 and 2021 were cited during 2022, normalized across the number of substantive research items the journal published in that window. A value of 5.5 is a strong result in pharmacology, a field where citation patterns are often concentrated in a small number of high-profile journals. Reaching a figure of this magnitude shortly after entering the index is notable, because new entrants typically take several years to build the citation base needed for competitive Impact Factors.

Equally significant is the journal’s position within its category. The Web of Science ranks journals in each subject category both by raw Impact Factor and by percentile, dividing them into quartiles designated Q1 through Q4. Ranking 48th out of 278 journals in Pharmacology and Pharmacy places the Journal of Pharmaceutical Investigation in Q1, the top quartile, roughly the top 17 percent of journals in the category. Many universities, funding agencies, and research assessment exercises treat Q1 status as a benchmark of excellence, and publishing in Q1 journals can influence hiring decisions, grant evaluations, and institutional rankings. For authors weighing where to submit their work, the combination of indexing, a healthy Impact Factor, and Q1 ranking makes the journal a considerably more attractive destination than it was before these achievements.

The mechanics behind these numbers deserve a closer look, because they illuminate how scientific reputation is quantified. The Impact Factor, despite its limitations and the ongoing debate about the role it should play in research assessment, remains the single most requested journal metric worldwide. It is computed by dividing the number of citations in a given year to items published in the journal during the preceding two years by the number of citable items, typically articles and reviews, published in those same two years. Distinguishing between citable and non-citable items, such as editorials, letters, and news pieces, is a frequent source of confusion and contention, but the underlying idea is straightforward: the metric aims to capture the average annual citation rate of a journal’s core scholarly output. A journal that publishes clinically and scientifically relevant work in drug development, formulation, pharmacokinetics, and therapeutic evaluation tends to attract steady citation attention from both academic and industry-affiliated researchers.

For the pharmaceutical research community specifically, the value of robust indexing extends beyond prestige metrics. Pharmaceutics and pharmacology are deeply interdisciplinary fields in which academic laboratories, hospital pharmacists, regulatory scientists, and industrial researchers all draw on the same literature. When a journal is comprehensively indexed in Science Citation Index Expanded, its articles become systematically searchable through Web of Science interfaces and through the many discovery platforms that build on its data. Systematic reviews, meta-analyses, and evidence syntheses, all of which are central to evidence-based pharmacotherapy, depend on comprehensive retrieval of relevant studies. Gaps in indexing can mean that important research is overlooked in these syntheses, so broad coverage benefits not just the journal but the accuracy and completeness of the scientific record as a whole.

The journal’s subject scope explains much of its appeal to contributors and readers. Publications of this kind typically cover investigations spanning drug delivery systems, pharmacokinetics and pharmacodynamics, clinical pharmacy practice, pharmaceutical technology, and therapeutic outcomes, providing a venue for work that bridges laboratory formulation science and clinical application. Research of this type sits at the intersection of chemistry, biology, medicine, and engineering, and its readership spans hospital pharmacies, academic departments of pharmaceutics, regulatory bodies, and pharmaceutical companies. A journal serving such a broad community has a strong incentive to maximize discoverability, since potential authors and readers are distributed across many countries and many professional settings. Indexing in the major citation databases is the most direct route to that visibility, and the Q1 ranking now makes the journal competitive for submissions that might previously have gone to longer-established titles.

It is also worth situating this achievement within broader trends in scholarly publishing. The pharmaceutical sciences have expanded dramatically over the past two decades, driven by biologics, novel drug delivery platforms, nanomedicine, and the growing importance of pharmacoeconomics and health outcomes research. This expansion has multiplied the number of journals competing for high-quality submissions, intensifying pressure on editors to demonstrate quality through metrics. At the same time, the research community and major funders have increasingly questioned overreliance on the Impact Factor, promoting alternatives such as article-level citation measures, preprint visibility, and responsible research assessment frameworks. Even so, indexing status and quartile rankings continue to function as practical gatekeepers in the day-to-day decisions of authors, librarians, and evaluators, which is why a journal’s successful entry into the Science Citation Index Expanded and its attainment of Q1 status remain genuinely newsworthy events for its community.

Looking ahead, the journal’s trajectory will depend on sustaining the editorial standards and citation performance that earned its current standing. Early Impact Factors can be volatile, and consolidating a Q1 position requires consistent publication of work that other researchers find useful and citable. If the journal maintains the quality and breadth that accompanied its 2021 indexing and its 2022 Impact Factor of 5.5, it is well positioned to strengthen its role as a reference point for pharmaceutical investigation internationally. For now, the combination of Science Citation Index Expanded coverage, a solid Impact Factor, and a top-quartile category ranking represents a clear vote of confidence from the bibliometric infrastructure that helps determine which journals the global research community reads, cites, and trusts.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Web of Science, Impact Factor, Q1 journal, Pharmacology and Pharmacy, journal indexing, citation metrics, pharmaceutical sciences, Clarivate, scholarly publishing

Abstracting and indexing services form the backbone of scientific communication infrastructure. When a journal is abstracted and indexed, its article records, including titles, author names, affiliations, abstracts and bibliographies, are systematically captured and catalogued in large bibliographic databases that researchers around the world use every day. Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and widely consulted of these services. Inclusion signals that a journal has passed editorial quality assessments covering peer-review rigor, publication ethics, editorial board composition, timeliness and international reach. For a pharmaceutical sciences journal, this recognition is particularly consequential because the field spans chemistry, pharmacology, formulation science, clinical investigation and regulatory science, and its researchers rely on comprehensive literature discovery to avoid duplication and build on prior findings.

The mechanics of indexing are less visible to readers but essential to how science circulates. Once a journal is accepted into SciSearch, every published article receives consistent metadata treatment: digital object identifiers are registered, citations between articles are tracked, and bibliometric algorithms can count how often a paper is referenced by later work. This citation network is what makes quantitative measures possible in the first place. Without structured indexing, citation counts would be fragmented across publisher websites and impossible to aggregate reliably. Indexed status also enables discovery through search platforms that institutions license, meaning a clinical pharmacist in Seoul or a formulation scientist in Boston encounters the journal’s content through the same trusted databases rather than through scattered web searches.

The impact factor of 5.5 reported for 2022 is calculated through a well-defined formula: it counts the citations received in that year by articles the journal published in the two preceding years, divided by the number of citable items, typically research articles and reviews, published in those same two years. A value of 5.5 means that, on average, recent articles in the journal were cited more than five times within roughly two years of publication, a strong performance in pharmacology and pharmacy, where citation patterns tend to be steadier and more gradual than in fast-moving fields such as molecular biology. The Q1 designation, derived from the journal’s position at 48 of 278 in its category, means it falls within the top quartile of titles, a threshold many institutions use as a benchmark for high-quality publication.

Within the pharmaceutical research community, these metrics carry practical weight. Journals that rank highly attract manuscripts from established laboratories, which in turn raises the technical quality and relevance of published work, creating a feedback loop of visibility and citation. For authors, publishing in an indexed, Q1-ranked journal ensures that their findings are counted in institutional assessments, grant applications and national research evaluation frameworks, many of which explicitly require Web of Science or Scopus inclusion. For readers, the ranking acts as a quality heuristic, a signal that the peer review process has historically filtered submissions with reasonable strictness. For librarians managing tight budgets, category rank and impact factor often inform subscription and renewal decisions, so a journal’s bibliometric performance directly shapes whether researchers can access it at all.

The journal’s subject area itself explains why this recognition resonates. Pharmaceutical investigation encompasses preclinical drug evaluation, pharmacokinetics and pharmacodynamics, novel delivery systems, nanotechnology-based formulations, biopharmaceutics and translational research linking laboratory findings to clinical outcomes. This is a domain where the pace of innovation is accelerating, driven by biologics, RNA therapeutics, targeted delivery platforms and computational drug design. Researchers in these areas depend on rapid, reliable access to peer-reviewed results, and a journal embedded in the core citation indexes effectively becomes part of the discipline’s shared memory. Articles that might otherwise remain niche become discoverable through citation chains, review articles and database alerts.

Entry into Science Citation Index Expanded in 2021 marked a milestone because that year is the starting point from which the journal’s citation record accumulates in the index. Impact factors for newly indexed journals require a lag period before the citation window contains sufficient data, so the 5.5 figure for 2022 represents the first full measurement of the journal’s citation performance within the service. Achieving a Q1 rank in that early measurement window is notable, since it indicates that work published in the journal was already being cited at a level competitive with long-established titles in pharmacology and pharmacy. It also suggests that the journal’s editorial scope aligns with active research fronts where citation activity is naturally concentrated.

Bibliometric indicators should nevertheless be read with nuance, a point widely acknowledged across the scholarly communication community. An impact factor describes the average citation behavior of a journal’s recent output, not the quality of any individual article, and citation counts vary by article type, topic popularity and review share. A journal publishing influential methodological reviews may see its average lifted relative to one focused on narrow empirical studies. Category rankings are more robust because they compare journals within the same discipline, but they still aggregate across subfields with different citation customs. Researchers and evaluators are therefore encouraged to treat the 5.5 impact factor and Q1 rank as one signal among several, alongside peer review reports, replication records and the actual content of the research itself.

For the journal’s editorial team, sustained indexing brings ongoing obligations. Indexed journals must maintain consistent publication schedules, transparent peer review workflows, correctable article records and adherence to publishing ethics standards. Data integrity, authorship transparency and conflict-of-interest disclosure are scrutinized both at submission and in periodic re-evaluation by indexing services, which can delist journals that fall short. This accountability framework benefits the entire pharmaceutical sciences community: it keeps the citation record trustworthy, ensures that meta-analyses and systematic reviews rest on verifiable sources, and protects early-career researchers who stake their careers on publications whose provenance must withstand institutional scrutiny.

As pharmaceutical research grows more interdisciplinary, the role of well-indexed journals as connective tissue between chemistry, biology, engineering and clinical medicine will only expand. The Journal of Pharmaceutical Investigation’s presence in Science Citation Index Expanded since 2021, combined with its 2022 impact factor of 5.5 and its Q1 standing at 48 of 278 in Pharmacology and Pharmacy, positions it as a reference point for researchers navigating this crowded landscape. Whether these metrics translate into durable scientific influence depends on the quality of the work the journal continues to publish and the rigor of its editorial processes, but the early indicators suggest that its articles are reaching the audiences positioned to build on them, cite them and, ultimately, convert them into better medicines.

Subject of Research: Abstracting, indexing and citation performance of the Journal of Pharmaceutical Investigation in Web of Science and pharmacology journal rankings

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Web of Science, impact factor, Q1 journal, Pharmacology and Pharmacy, pharmaceutical sciences, bibliometrics, scholarly publishing, citation metrics

Abstracting and indexing, often abbreviated as A&I, is the process by which bibliographic databases catalog scholarly articles, capturing their titles, authors, abstracts, keywords and citations in structured records that can be searched, sorted and analyzed at scale. For researchers, these databases are the primary discovery tools of modern science: a paper that is not indexed in the major services is effectively invisible to most of the global research community, no matter how rigorous its methods or how significant its findings. For journals, inclusion in prestigious indexes is both a badge of quality and a practical necessity, because libraries, funders and tenure committees routinely evaluate publications based on where they are indexed and what citation metrics those indexes generate.

The Journal of Pharmaceutical Investigation has been abstracted and indexed in the Science Citation Index Expanded, commonly known as SciSearch, since 2021. The Science Citation Index Expanded is maintained by Clarivate as part of the Web of Science platform, one of the most authoritative citation databases in the world. It traces its lineage to the original Science Citation Index created by Eugene Garfield in the 1960s, a pioneering effort to map the flow of ideas through the scientific literature by tracking which papers cite which. That citation network remains the foundation of modern bibliometrics, and inclusion in the expanded index signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial content, international diversity and citation behavior.

Once a journal is indexed in the Science Citation Index Expanded, it becomes eligible for the Journal Impact Factor, the single most widely cited metric in scholarly publishing. The impact factor is calculated by dividing the number of citations received in a given year by items published in the journal during the two preceding years. A journal’s 2022 impact factor of 5.5 therefore means that, on average, articles published in 2020 and 2021 were cited 5.5 times each during 2022. While the metric has well-documented limitations, it remains a shorthand that researchers, institutions and publishers watch closely, and movement in the rankings can shape manuscript submission patterns, editorial strategies and even national research assessment frameworks.

A ranking of 48 out of 278 journals places the Journal of Pharmaceutical Investigation in the first quartile, or Q1, of the Pharmacology and Pharmacy category, meaning it sits among the top 25 percent of titles in its field. Quartile rankings are derived by ordering journals within a category by impact factor and dividing them into four equal bands. Q1 status is particularly meaningful in pharmacology, one of the most competitive categories in the Web of Science, where established titles with decades of history and enormous submission volumes compete for citation attention. For a journal to reach and hold a Q1 position, its published work must not only meet high editorial standards but also resonate with a broad community of researchers who choose to cite it in their own studies.

The journal’s subject matter helps explain that resonance. Pharmaceutical investigation encompasses the entire lifecycle of a drug, from early discovery and formulation science through pharmacokinetics, pharmacodynamics, clinical evaluation, manufacturing quality and post-marketing surveillance. Research in this space is inherently translational, connecting laboratory findings to therapeutic outcomes, and it draws citations from a wide range of adjacent disciplines, including biotechnology, nanomedicine, regulatory affairs and clinical pharmacy. Journals that publish work spanning this breadth tend to accumulate citations from many communities, which strengthens their bibliometric performance and, in a self-reinforcing loop, attracts further high-quality submissions from authors seeking visibility.

The timing of the journal’s SciSearch inclusion in 2021 and its subsequent impact factor performance illustrates a broader dynamic in scholarly publishing. New or newly indexed journals typically need two full publication cycles before their first official impact factor can be calculated, because the metric depends on a two-year citation window. The years immediately following indexing are therefore critical: editors work to commission review articles, which are disproportionately cited, and to attract original research from prominent groups, knowing that early citation performance will set the trajectory of the journal’s metrics for years to come. Achieving a 5.5 impact factor within a short period of entering the index suggests that the journal’s editorial strategy and its community of contributors have aligned effectively with the citation patterns of contemporary pharmaceutical research.

Behind the headline numbers lies an elaborate ecosystem of data infrastructure. When an article is published, its metadata are transmitted to indexing services, where they are normalized against standards for author names, affiliations, funding information and references. Citation links are then resolved and aggregated, feeding not only the impact factor but also a family of related indicators, including the five-year impact factor, the immediacy index, the cited half-life and the eigenfactor, each of which captures a different dimension of a journal’s scholarly footprint. Databases also power literature search engines, reference managers and systematic review workflows, meaning that indexing quality directly affects how efficiently science itself proceeds. Errors or gaps in indexing can delay discoveries, skew bibliometric analyses and misrepresent the provenance of ideas.

For the pharmaceutical sciences specifically, robust indexing carries practical stakes beyond prestige. Systematic reviews and meta-analyses, which underpin clinical guidelines and regulatory decisions, depend on comprehensive database coverage to identify all relevant evidence. Pharmacovigilance researchers tracking adverse events, formulation scientists surveying delivery technologies and health economists assessing drug value all rely on indexed literature to build complete pictures of the evidence base. A journal’s presence in the Science Citation Index Expanded therefore contributes to the reliability of the evidence synthesis on which drug safety and efficacy decisions ultimately rest, a responsibility that extends well beyond the publishing world into patient care.

The Journal of Pharmaceutical Investigation’s Q1 standing in 2022 is a snapshot of a competitive and rapidly evolving field, and maintaining that position will require continued editorial rigor as publishing itself changes. Preprint servers, open access mandates, alternative metrics and new assessment frameworks such as the Declaration on Research Assessment are reshaping how scholarly value is measured, and citation-based indicators are increasingly scrutinized for the ways they can be gamed or misapplied. Yet for now, the combination of SciSearch indexing and a 5.5 impact factor confirms the journal’s place among the leading venues for pharmaceutical research, offering authors a platform with global discoverability and offering readers a curated window into the science that moves molecules from the bench to the bedside.

Subject of Research: The indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor and Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, abstracting and indexing, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, pharmaceutical sciences, bibliometrics, Clarivate

Abstracting and indexing is the infrastructure that underpins the modern scientific record. When a journal is accepted into a major citation index, its articles become discoverable through the databases that scientists, clinicians, and institutions rely on every day to survey the literature. The Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and influential of these databases. Inclusion signals that a journal has passed rigorous editorial evaluation covering publishing standards, peer-review integrity, international editorial breadth, and citation behavior. For a journal to be abstracted and indexed in SciSearch from 2021 onward means that every article it publishes is now woven into the global web of citation data that powers literature searches, systematic reviews, bibliometric analyses, and institutional assessments.

The consequences of that inclusion ripple outward quickly. A paper on a novel nanoparticle formulation or a new approach to oral drug absorption that might once have been seen primarily by the journal’s existing readership can now surface in the reference lists, alerts, and search results of researchers on every continent. Citations accumulate, and those citations feed directly into the journal’s Impact Factor, the most scrutinized single number in scholarly publishing. The 2022 Impact Factor of 5.5 for the Journal of Pharmaceutical Investigation reflects the average number of times articles published in the preceding two years were cited during 2022. Crossing the threshold into double-digit percentile territory in a crowded category is a meaningful achievement that reflects both the quality of the work the journal publishes and the engagement of the community that reads it.

The ranking attached to that Impact Factor deserves particular attention. The Journal of Pharmaceutical Investigation’s position of 48 out of 278 journals in the Pharmacology and Pharmacy category places it in the Q1 band, the top quartile of its discipline. Quartile rankings divide a category’s journals into four groups by citation performance, and Q1 status is frequently used by funding agencies, hiring committees, and universities as shorthand for excellence. In a field as broad and competitive as pharmacology and pharmacy, which spans everything from medicinal chemistry and pharmacokinetics to clinical pharmacy practice and health economics, occupying the top quartile requires a journal to be cited at rates that exceed roughly three-quarters of its peers. That is a demanding standard in a category where established, decades-old titles compete for the same citations.

Understanding why these metrics matter requires a look at how scientific visibility actually works. Researchers cannot read everything; the volume of pharmaceutical literature published each year runs to hundreds of thousands of articles. Search engines, recommendation tools, and citation databases act as filters, and journals that are indexed in the major databases are dramatically more likely to appear in those filters. An article that is not indexed is, for practical purposes, invisible to much of the global research community, no matter how rigorous its methods or how important its findings. Indexing in SciSearch therefore functions as a guarantee of discoverability, ensuring that the pharmaceutical research published in the journal can be found by the translational scientists, formulation chemists, regulatory affairs professionals, and clinicians who might build on it.

For authors, the practical implications are considerable. Early-career scientists choosing where to submit their work weigh the visibility of a journal heavily, because citations shape careers: grant applications, promotions, and tenure decisions all lean on publication records. A journal with a 5.5 Impact Factor and a Q1 ranking offers a persuasive combination of reach and prestige, particularly for interdisciplinary work in drug delivery, pharmacokinetics, and pharmaceutical technology where the readership spans pharmacy, chemistry, materials science, and medicine. Authors also gain the assurance that their work will be captured in institutional repositories, reported in faculty citation profiles, and counted in national research assessments that draw on Web of Science data.

For readers and research institutions, indexing and citation metrics serve a different but equally important function: they act as quality signals in an environment of information overload. Libraries use indexing status and citation performance to make subscription decisions, allocating finite budgets toward journals that their communities actually use and cite. Systematic reviewers and meta-analysts, whose syntheses of the literature inform clinical guidelines and regulatory decisions, depend on indexed databases to ensure their searches are comprehensive. When a journal is reliably indexed, reviewers can trust that its content will be captured in their search strategies, reducing the risk that important evidence is overlooked. In pharmaceutical research, where a missed finding can influence drug development decisions with billions of dollars and patient safety at stake, that reliability carries real weight.

The journal’s trajectory also illustrates broader dynamics in scholarly publishing. Impact Factors are recalculated annually and can shift with changes in a field’s citation culture, the timing of highly cited articles, and the growth of a journal’s readership. A journal that earns a strong Impact Factor often enters a virtuous cycle: greater visibility attracts stronger submissions, stronger submissions attract more citations, and more citations reinforce the metrics that drew authors in the first place. Entering the Science Citation Index Expanded in 2021 gave the Journal of Pharmaceutical Investigation access to exactly this cycle, and the 2022 figure of 5.5 provides early evidence that the cycle is turning favorably. Sustaining that position will depend on continued editorial rigor, timely publication, and the ability to anticipate where pharmaceutical science is heading next.

Pharmaceutical investigation itself is a field in the midst of remarkable ferment, and the research indexed under this journal’s banner reflects that energy. Drug delivery science is being reshaped by lipid nanoparticles, antibody-drug conjugates, and mRNA platforms whose importance the pandemic made unmistakable. Pharmacokinetic modeling increasingly incorporates artificial intelligence and physiologically based simulation to predict human outcomes from preclinical data. Formulation scientists are tackling biologics, cell therapies, and nucleic acid medicines that defy the traditional tools of the discipline. A Q1-ranked journal embedded in this landscape functions as a convergence point, drawing together the pharmacists, chemical engineers, clinicians, and data scientists whose combined work determines whether laboratory discoveries become medicines on pharmacy shelves.

As the Journal of Pharmaceutical Investigation continues its indexed run, its citation record will be watched not only by its editors and authors but by the wider community that relies on bibliometric indicators to navigate an expanding literature. The 2022 Impact Factor of 5.5 and the Q1 rank of 48 out of 278 in Pharmacology and Pharmacy establish a clear benchmark, and they assure researchers that work published in the journal will be counted, cited, and seen. In a scientific ecosystem where discoverability can determine whether a finding shapes a new therapy or fades unread, the combination of rigorous peer review, inclusion in the Science Citation Index Expanded, and strong citation performance represents the difference between publishing and truly communicating. For pharmaceutical science, one of the most consequential research endeavors of the age, that distinction matters.

Subject of Research: Abstracting, indexing, and citation performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, Science Citation Index Expanded, SciSearch, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, drug delivery, scholarly publishing, pharmaceutical sciences

To understand why this matters, it helps to unpack what abstracting and indexing actually involves. Abstracting services capture the summary, or abstract, of each article along with its metadata: authors, affiliations, keywords and journal details. Indexing goes a step further, embedding that metadata into structured databases that can be searched, cross-referenced and analyzed at scale. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is among the most selective of these databases. Journals are admitted only after an editorial evaluation that examines editorial rigor, peer-review integrity, the international diversity of authorship, regularity of publication and the citation behavior of the published content. Once a journal is accepted, every article it publishes is ingested, its reference list is parsed, and each cited reference is linked to the database’s network of scholarly records.

That reference linking is what makes citation metrics possible. When a paper published in the Journal of Pharmaceutical Investigation is cited by a researcher anywhere in the indexed literature, the event is recorded, timestamped and attributed. Aggregated over time, these events feed the Journal Impact Factor, a metric calculated annually in Clarivate’s Journal Citation Reports. The formula is deceptively simple: the 2022 impact factor counts citations made in 2022 to items the journal published in 2020 and 2021, divided by the number of citable items, typically articles and reviews, published in those same two years. A score of 5.5 therefore means that, on average, each citable paper from the journal’s 2020 and 2021 volumes was cited 5.5 times in the following year by the indexed literature.

The category ranking adds a second layer of interpretation. Pharmacology and Pharmacy is one of the largest and most competitive categories in the Journal Citation Reports, containing 278 journals that range from basic molecular pharmacology to clinical therapeutics and formulation science. Ranking 48th in that field places the journal in the 17th percentile, comfortably inside the Q1 quartile that spans the top 25 percent of titles. Quartile assignments matter in practical academic life: hiring committees, grant agencies and national evaluation systems in many countries use Q1 status as a shorthand for journal prestige, and some funding bodies explicitly require that publications appear in Q1 or Q2 journals to count toward a researcher’s track record.

For a journal focused on pharmaceutical investigation, the indexing milestone also changes how its content circulates. Articles in the Science Citation Index Expanded are surfaced through Web of Science searches used daily by millions of researchers, and the indexed metadata feeds into citation alerts, research profiles and institutional dashboards. Downstream services, including citation managers, discovery layers at university libraries and literature-screening tools used in drug-safety reviews, draw on the same structured records. In practical terms, a pharmacokinetics study or a novel drug-delivery paper published in the journal is now far more likely to be found, cited and built upon by teams working in formulation chemistry, clinical pharmacy and regulatory science around the world.

The timing is notable against the backdrop of a broader debate about how scientific quality should be measured. The impact factor, conceived in the 1960s as a tool for librarians deciding which journals to subscribe to, has become one of the most scrutinized numbers in science. Critics, including the signatories of the San Francisco Declaration on Research Assessment, argue that the metric is easily skewed by a small number of highly cited papers, that it differs across fields in ways that make cross-disciplinary comparisons misleading, and that it says nothing about the quality of any individual article. Defenders counter that, for all its flaws, the impact factor remains a transparent, reproducible and widely understood indicator of a journal’s average citation performance, and that quartile rankings within a single field, such as Pharmacology and Pharmacy, offer a fairer like-for-like comparison.

Clarivate itself has been evolving the ecosystem around these metrics. In recent years the Journal Citation Reports have added supplementary indicators, including the Journal Impact Factor percentile, the five-year impact factor and the Eigenfactor-style measures that weight citations by the prestige of the citing journal. The 2023 release extended impact factors to all journals in the Web of Science Core Collection, including those in the Emerging Sources Citation Index, a change that increased the number of titles receiving the metric from roughly 9,500 to more than 21,000. For newly indexed journals, this expansion means that citation performance is visible almost immediately after entry into the collection, rather than after the traditional multi-year waiting period, accelerating the feedback loop between publication and measurable scholarly impact.

Behind the headline numbers lies a labor-intensive editorial operation. Journals seeking Science Citation Index Expanded inclusion must demonstrate consistent publication schedules, robust peer-review processes, ethical publishing practices aligned with guidelines from the Committee on Publication Ethics, and content that is genuinely international in authorship and readership. Clarivate’s editorial development team also assesses whether the journal fills a distinctive niche relative to existing coverage, a criterion that rewards publications addressing specific research communities, such as pharmaceutical formulation, biopharmaceutics and translational drug research, rather than duplicating well-served areas. Once admitted, journals remain under continuous review, and titles whose quality or citation performance deteriorates can be flagged or delisted, a mechanism that has drawn increased attention as the publishing industry confronts paper mills and predatory outlets.

For researchers deciding where to submit their work, the combination of Q1 status and a 5.5 impact factor signals that the journal now competes directly with established titles in pharmaceutical science. Authors in drug delivery and pharmaceutical technology often weigh several factors beyond the impact factor: the speed of peer review, open-access options and licensing terms, the journal’s readership among industrial and regulatory scientists, and how quickly an accepted paper becomes visible in indexing services. Full indexing in the Science Citation Index Expanded addresses the visibility component decisively, since every accepted article enters the citation network from the point of indexing onward, accumulating the references that will determine future metric cycles.

The broader lesson from the journal’s trajectory is that scholarly visibility is built in layers: rigorous peer review attracts strong papers, strong papers attract citations, citations drive impact factors, and impact factors, in turn, attract more strong submissions. Indexing in the Science Citation Index Expanded is the infrastructure that makes this cycle measurable. As the 2023 and 2024 publication years accumulate citations, the journal’s position within the Pharmacology and Pharmacy rankings will be tested against 277 competitors, many of them far larger and longer-established. Whether it consolidates its Q1 standing or climbs higher, its entry into the citation mainstream marks the moment when its research output became fully countable in the quantitative machinery that increasingly shapes careers, funding decisions and the global flow of pharmaceutical science.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its Q1 impact factor ranking in pharmacology

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, Web of Science, Journal Impact Factor, Clarivate, Q1 journal, Pharmacology and Pharmacy, citation analysis, abstracting and indexing, pharmaceutical science, research metrics, peer review

To understand why this matters, it helps to unpack what indexing in the Science Citation Index Expanded actually means. The Science Citation Index Expanded is one of the core citation databases maintained within the Web of Science, the citation ecosystem originally built on Eugene Garfield’s pioneering work at the Institute for Scientific Information. Inclusion is not automatic. Journals seeking coverage undergo a rigorous evaluation process in which publishers submit documentation of editorial standards, peer review practices, editorial board composition, publication ethics policies, and the international diversity of authorship. Clarivate’s editorial development team assesses whether the journal meets the quality thresholds for foundational coverage and whether its citation performance justifies admission. Being accepted into SciSearch in 2021 signaled that the Journal of Pharmaceutical Investigation had cleared one of the most demanding quality gates in scholarly publishing, a gate that thousands of journals worldwide never pass.

Indexing, in turn, is the precondition for the metric that has become the lingua franca of journal evaluation: the Impact Factor. Calculated annually by Clarivate from the Journal Citation Reports, the Impact Factor for a given year counts the number of citations received in that year by items published in the journal during the two preceding years, divided by the number of citable items published in those same two years. A value of 5.5 for 2022 therefore means that, on average, each citable article published in the journal during 2020 and 2021 was cited 5.5 times in 2022. Because the journal entered SciSearch in 2021, this figure reflects a relatively early citation window, which makes the performance even more striking. New entrants to the citation index typically take several years to accumulate visibility, so a first-quartile placement so soon after admission suggests an unusually rapid adoption by the research community.

The quartile classification adds another layer of meaning. Clarivate assigns journals to categories, and within each category journals are ranked by their Impact Factor and divided into quartiles, with Q1 representing the top 25 percent of titles. The Pharmacology and Pharmacy category is one of the largest and most competitive in the entire Web of Science taxonomy, encompassing 278 journals that range from mega-journals of translational medicine to highly specialized publications in toxicology, drug metabolism, and clinical pharmacy. Ranking 48th in that field places the Journal of Pharmaceutical Investigation firmly within the upper tier of pharmacological publishing, alongside far more established titles with decades of citation history. For authors weighing where to submit manuscripts, quartile placement often carries practical consequences, because funding agencies, promotion committees, and doctoral programs in many countries explicitly require publication in Q1 journals.

The journal’s subject scope helps explain its rising citation profile. Pharmaceutical investigation as a discipline sits at the crossroads of pharmaceutics, biopharmaceutics, drug delivery, pharmacokinetics, and formulation science, and it increasingly absorbs techniques from nanotechnology, materials science, and computational modeling. Research published under this umbrella includes studies of controlled-release systems, lipid-based carriers, polymeric nanoparticles, dissolution testing, bioavailability enhancement, and the physicochemical characterization of novel dosage forms. In recent years the field has been swept up in broader currents reshaping the pharmaceutical sciences, including the explosion of interest in mRNA delivery platforms, the refinement of long-acting injectable formulations, and the application of machine learning to formulation optimization. Journals positioned at the center of these currents tend to attract high citations, because their articles serve as methodological references for large and fast-moving research communities.

The journal in question is published by Springer, one of the major international scientific publishers, and the pharmaceutical sciences have long been a strategic area for the company’s portfolio. The relationship between publisher and index provider is central to the economics of modern scholarly communication. Publishers invest in editorial infrastructure, peer review management, digital preservation, and dissemination platforms, while citation index providers aggregate the resulting literature into evaluative frameworks that institutions use to allocate resources. The feedback loop can be powerful. Indexing increases discoverability through Web of Science searches, discoverability drives downloads and citations, and citations raise the Impact Factor, which in turn attracts stronger submissions from researchers seeking maximum visibility for their work. The journal’s 2022 numbers suggest that this flywheel has begun to turn decisively.

It is worth pausing on how rapidly scholarly metrics themselves have evolved, because the Impact Factor, despite its ubiquity, is a blunt instrument. Critics have long noted that the two-year citation window disadvantages slow-moving fields, that citation distributions within journals are heavily skewed so that a small fraction of papers accounts for most citations, and that aggregate scores can be gamed through editorial strategies such as publishing review articles, which attract citations at a higher rate than primary research. The San Francisco Declaration on Research Assessment, signed by thousands of journals and institutions, urges evaluators to look past journal-level metrics to the actual content and quality of individual papers. Yet the practical reality in much of the world, particularly in Asia, Europe, and Latin America, is that Impact Factors and quartiles remain embedded in grant applications, hiring decisions, and national research assessment exercises. Against that backdrop, a journal’s climb into Q1 translates directly into the career incentives of working scientists.

The pharmaceutical sciences occupy a distinctive position in this evaluative landscape because the field straddles academia and industry. Research on drug delivery and formulation frequently progresses from laboratory bench to clinical application, and the intellectual property and commercial stakes involved mean that citation patterns differ from those in purely academic disciplines. Industry scientists read and cite the pharmaceutical technology literature when designing development programs, and regulatory science considerations, such as bioequivalence standards and dissolution specifications, generate steady citation demand for foundational methodology papers. A Q1 journal in this space therefore functions not only as an academic outlet but as a shared reference point connecting university labs, contract research organizations, generic drug manufacturers, and innovator pharmaceutical companies across dozens of countries.

The timeline of the journal’s ascent is also instructive for understanding how new journals break through in a crowded market. Acceptance into SciSearch in 2021 followed the standard probationary logic of the Web of Science: emerging journals receive partial coverage initially, typically tracking newly published content, and their citation records build as indexed material accumulates. Within a single full cycle the journal achieved an Impact Factor of 5.5 and a category rank of 48 of 278, performance that many long-established titles would consider strong. This acceleration is characteristic of the current era, in which digital distribution, social media amplification, and global submission pipelines allow a well-edited journal to reach its audience far faster than was possible in the print-dominated decades when citation reputations took a generation to form.

For observers of scientific publishing, the broader lesson is that the map of influential journals is not fixed. The Pharmacology and Pharmacy category continues to expand, the tools for evaluating research continue to evolve, and the competition for high-quality manuscripts intensifies as publishers launch new open-access titles and established journals adjust their strategies. The Journal of Pharmaceutical Investigation’s 2022 standing, with an Impact Factor of 5.5 and a first-quartile ranking among 278 pharmacology journals, demonstrates how indexing prestige, editorial focus, and community engagement combine to reshape that map. Whether the journal can sustain and improve its position in future Journal Citation Reports will depend on the same factors that drive all scholarly success: the quality and novelty of the science it publishes, the rigor of its peer review, and its ability to serve as an indispensable resource for the researchers advancing drug development worldwide.

Subject of Research: Indexing and citation performance of the Journal of Pharmaceutical Investigation in the Web of Science Pharmacology and Pharmacy category

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Impact Factor, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, quartile ranking, citation metrics, drug delivery, pharmaceutical sciences, Springer, Q1 journal

Abstracting and indexing is the infrastructure that makes scientific literature discoverable. When a journal is indexed in a database such as Science Citation Index Expanded, its articles are cataloged with standardized metadata, including author names, affiliations, abstracts, keywords, and cited references. This allows search engines and bibliographic databases to retrieve the work reliably when researchers query the literature. Without such indexing, even high-quality research risks becoming effectively invisible, buried in a journal that major discovery platforms do not cover. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is one of the most selective and widely used indexes in science, and inclusion in it signals that a journal has passed editorial and quality evaluations covering publishing standards, international diversity, peer-review rigor, and citation impact.

The 2022 Impact Factor of 5.5 reflects how often articles published in the journal during 2020 and 2021 were cited in 2022, averaged across the number of substantive items published in that window. Impact Factors are calculated annually from the citation data underlying the Journal Citation Reports, and they remain the single most quoted metric in journal evaluation despite ongoing debate about their limitations. A score of 5.5 places the Journal of Pharmaceutical Investigation comfortably above the median for pharmacology journals, a field that spans basic drug discovery, formulation science, pharmacokinetics, clinical pharmacology, and regulatory science. The Q1 designation, meaning the top quartile of the category, is a threshold that many institutions use when assessing whether a publication outlet meets quality expectations for faculty evaluation, grant reporting, and doctoral training requirements.

The journal’s rise through the rankings has been relatively rapid. Its inclusion in Science Citation Index Expanded dates to 2021, meaning that within roughly two years of entering the index it climbed into the upper quarter of a competitive category containing 278 journals. Pharmacology and Pharmacy is one of the most heavily populated categories in the Journal Citation Reports, encompassing everything from specialist translational titles to large general pharmacology journals, so a rank of 48 out of 278 represents a meaningful position rather than a marginal one. Analysts of scholarly publishing note that newly indexed journals often experience a citation lag, because articles published before indexing are not captured in Impact Factor calculations and it takes time for the journal to accumulate visibility in databases that researchers consult daily. Beating that lag and reaching Q1 quickly suggests strong citation performance for the recently published work that the metric does capture.

For the pharmaceutical research community, the journal’s visibility matters in practical terms. The Journal of Pharmaceutical Investigation publishes work on drug delivery systems, pharmacokinetics and pharmacodynamics, novel formulations, nanomedicine approaches, and investigative studies bridging laboratory findings and clinical application. Researchers in these areas compete for attention in a literature that grows by hundreds of thousands of articles each year. Indexing in SciSearch ensures that their papers appear in Web of Science searches, are linked through citation networks to related work, and are counted in the bibliometric profiles that individual scientists build over their careers. Citation counts drawn from indexed databases feed into h-index calculations, institutional rankings, and the evaluation criteria of major funding agencies, so the difference between an indexed and a non-indexed journal can directly affect a researcher’s professional trajectory.

The broader context is a scholarly publishing industry undergoing rapid change. Open access models, preprint servers, and alternative metrics have diversified how research is disseminated and assessed, yet established indexes such as Science Citation Index Expanded continue to function as gatekeepers of legitimacy. Clarivate applies a multi-stage evaluation to candidate journals, examining editorial consistency, peer-review integrity, the international composition of authorship and editorial boards, citation behavior, and adherence to publishing ethics standards. Journals that fail to meet these criteria are excluded, and those already indexed face periodic re-evaluation, with titles that decline in quality or engage in citation manipulation subject to delisting. In this environment, the Journal of Pharmaceutical Investigation’s sustained inclusion and its Q1 performance indicate that its editorial processes and citation record have withstood scrutiny from the field’s most influential bibliometric authority.

Librarians and research administrators pay close attention to these indicators when making collection and policy decisions. University libraries with constrained budgets rely on indexing status and quartile rankings to decide which subscriptions to maintain, while research offices frequently maintain lists of approved outlets for publication based on Journal Citation Reports quartiles. A Q1 pharmacology journal with a 5.5 Impact Factor is likely to appear on such lists, channeling submissions toward it and reinforcing the citation cycle that sustains its metrics. Critics of this feedback loop argue that it concentrates attention on already prominent journals and can disadvantage regional or emerging titles, but the practical reality for authors is that indexing and quartile remain decisive factors in where they send their manuscripts, particularly in applied fields where industry and regulatory audiences consult the indexed literature.

The journal’s metrics also carry weight internationally, particularly in Asia, where pharmaceutical sciences research output has expanded dramatically over the past two decades. The Journal of Pharmaceutical Investigation has historically served as a venue for research from pharmacology and pharmaceutics communities across Asia and beyond, and its strengthened bibliometric profile gives authors in these regions a high-visibility home for work that might otherwise migrate to Western-centric titles. Bibliometric studies have documented the growing share of global pharmaceutical research produced in countries such as South Korea, Japan, China, and India, and journals that combine regional roots with international indexing standards are well positioned to capture this expanding output. The 2022 figures suggest that the journal is successfully converting that growth into citation impact recognized at a global level.

Looking ahead, the journal’s trajectory will depend on maintaining the editorial quality and citation performance that underpin its current standing. Impact Factors fluctuate from year to year, and a single weak publication cycle can shift a journal’s quartile position in a category as densely packed as Pharmacology and Pharmacy. At the same time, the ongoing evolution of research assessment, including movements such as the Declaration on Research Assessment that encourage evaluation beyond a single metric, may gradually change how much weight the Impact Factor carries. For now, however, the combination of Science Citation Index Expanded coverage, a 5.5 Impact Factor, and a Q1 ranking gives the Journal of Pharmaceutical Investigation a strong position in the competitive market for pharmaceutical sciences research, and a clear signal to authors and readers about the visibility their work can expect to achieve.

Subject of Research: Abstracting and indexing status and citation impact of the Journal of Pharmaceutical Investigation

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, pharmacology, pharmacy, Q1 journal, Springer, bibliometrics, scholarly publishing

Abstracting and indexing may sound like a dry administrative exercise, but for working scientists it is the infrastructure that determines whether their work is ever seen. When a journal is indexed in a major citation database, every published article gains a standardized record: a structured abstract, author affiliations, subject headings, bibliographic metadata and, critically, a persistent link that other researchers can follow from a search result to the full text. Without that record, even excellent research risks becoming invisible, buried in a journal that search engines and literature reviews rarely surface. Indexing is therefore the mechanism by which a journal’s content enters the bloodstream of scientific communication.

Science Citation Index Expanded, maintained within the Web of Science ecosystem, is one of the most selective and widely recognized of these databases. Journals admitted to the index undergo evaluation of their editorial rigor, publishing standards, peer-review processes, international authorship and citation behavior. Inclusion since 2021 means that all content published by the Journal of Pharmaceutical Investigation from that point onward is systematically captured, allowing citation links to accumulate year by year. This is a prerequisite for any journal that hopes to receive a Journal Impact Factor, the most discussed single number in scholarly publishing.

The Journal Impact Factor itself is a deceptively simple calculation. In any given year, it counts the citations received in that year by items a journal published in the two preceding years, divided by the number of substantive, citable items, chiefly research articles and reviews, published in those same two years. A 2022 impact factor of 5.5 therefore reflects citations earned during 2022 by material published in 2020 and 2021. That figure indicates that, on average, each citable article from those years was cited more than five times within the measurement window, a level of citation intensity that places the journal firmly among the most influential publications in its discipline.

Just as significant as the raw score is the category ranking: 48th out of 278 journals in Pharmacology and Pharmacy. Citation density varies enormously between fields, so a raw impact factor means little until it is contextualized within a discipline. Quartile placement provides that context. A first-quartile position, corresponding to the top 25 percent of journals in the category, signals to authors, reviewers, librarians and funding bodies that the journal sits within the leading tier of venues for pharmaceutical research. It is this rank, rather than the number alone, that most often determines where researchers choose to submit their best work.

For pharmaceutical scientists, the practical consequences are concrete. A Q1 journal with a 5.5 impact factor becomes a preferred destination for studies on novel drug delivery systems, pharmacokinetics, formulation science, nanotechnology-based therapeutics and clinical investigation of new compounds. Authors gain the assurance that their papers will be read by a broad, international audience and that citations will be tracked and attributed correctly. Readers gain the assurance that the journal’s editorial standards have been vetted by an independent indexing body. Institutions, in turn, use these indicators when evaluating faculty productivity, since indexed, highly ranked publications carry more weight in hiring, promotion and grant assessments.

The timing of the indexing also matters. A journal’s early years in a citation index are typically characterized by incomplete citation trails, because it takes time for the database to record references pointing back to newly indexed content. As the 2021 entry point recedes, successive impact factor cycles will draw on an increasingly complete record of the journal’s output. This dynamic often produces a period of citation growth, as previously published articles continue to accrue citations while the denominator of citable items stabilizes. The 2022 figure of 5.5 should therefore be read not as a static endpoint but as a data point in an ongoing trajectory of the journal’s scientific footprint.

It is worth pausing on why metrics like these attract such intense attention, and also on their limits. The Journal Impact Factor was originally designed as a library-management tool, a way to help librarians decide which journals to subscribe to, not as a measure of the quality of any individual paper. A citation to an article can be positive, negative or merely incidental, and citation counts are influenced by article type, review coverage and field trends. Editors and bibliometricians have long cautioned against grading individual researchers by the impact factor of the journals in which they publish. Nevertheless, at the level of the journal as a whole, the metric remains a fast, transparent and universally understood signal of scholarly influence, and quartile rankings in particular continue to shape real decisions across the research enterprise.

Within pharmaceutical science specifically, the value of strong indexing infrastructure is amplified by the field’s translational character. Research published in these pages informs drug formulation, bioavailability enhancement, controlled-release technology, pharmacoeconomics and regulatory science, and its audience spans academic laboratories, industrial research and development groups, clinical pharmacologists and regulatory reviewers. When a study on a novel nanoparticle carrier or an improved oral delivery platform is properly abstracted and indexed, it can be retrieved by a formulator searching for prior art, by a regulatory scientist drafting a dossier or by a clinician weighing a new therapeutic approach. Each of those retrieval events is a potential citation, and each citation strengthens the record on which the journal’s ranking rests. Indexing, citation and scientific progress form a single feedback loop.

The Journal of Pharmaceutical Investigation’s combined achievement, inclusion in Science Citation Index Expanded since 2021, a 2022 Journal Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, therefore represents more than a publishing success. It reflects the cumulative choices of thousands of authors who selected the journal as the home for their work, the reviewers and editors who upheld its scientific standards, and the researchers worldwide whose citations now register in the databases that measure contemporary science. As the journal’s indexed archive matures, its bibliometric record will continue to evolve, and the pharmaceutical research community will be watching how that trajectory develops in the annual release of citation reports to come.

Beyond the headline numbers, the mechanics of how a journal enters and moves through the citation ecosystem deserve closer attention. Science Citation Index Expanded traces its lineage to the Citation Index for Science created in the 1960s, when bibliographers first demonstrated that references embedded in published papers could be aggregated into a searchable network of scholarly influence. That insight, that citations function as explicit acknowledgments of prior intellectual debt, remains the conceptual foundation of modern bibliometrics, and every impact factor calculated today descends from it.

The distinction between being indexed and being measured is also worth clarifying. Journals admitted to Science Citation Index Expanded receive standardized bibliographic records and become part of the citation network, but the Journal Impact Factor itself is released through a separate annual reporting process that evaluates journals after a period of consistent indexing. This staged progression explains why newly indexed journals often need several annual cycles before their metrics stabilize, and why the 2022 assessment of the Journal of Pharmaceutical Investigation represents an early but meaningful reading of its citation performance rather than a mature one.

For authors deciding where to submit, indexing status interacts with other practical considerations. Pharmaceutical research is a fast-moving field in which preprints, conference proceedings and patent literature all compete for attention, so the assurance that a journal’s records are systematically captured and cross-linked carries real weight. Standardized metadata also enables bibliometric tools to disambiguate authors with similar names, connect related datasets and track the diffusion of a finding across disciplines, functions that become increasingly important as pharmaceutical science grows more interdisciplinary, drawing on chemistry, biology, engineering and clinical medicine simultaneously.

The category in which the journal is ranked deserves note as well. Pharmacology and Pharmacy is a broad and crowded classification that encompasses basic pharmacological research, drug design, clinical therapeutics and pharmacy practice, meaning journals compete for citation attention across quite different audiences. Achieving a position within the top quartile of such a heterogeneous category suggests that the journal’s content resonates beyond a narrow specialty, attracting citations from multiple subfields rather than from a single tightly knit community. Cross-disciplinary citation of this kind is often cited by editors as a sign of durable relevance.

Finally, the broader publishing environment shapes how such metrics should be interpreted. Scholarly communication is undergoing sustained change, with open access models, alternative metrics and funder mandates altering how research is disseminated and discovered. Citation-based measures remain the most established currency of journal evaluation, but they increasingly sit alongside downloads, altmetric attention and policy citations in a fuller picture of impact. Within that evolving landscape, a journal that combines rigorous peer review, international reach and strong indexed performance is well positioned to remain a trusted venue as the standards by which science is assessed continue to develop.

Subject of Research: Abstracting and indexing of pharmaceutical research journals and citation metrics

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, SciSearch, Journal Impact Factor, pharmacology, pharmacy, Q1 journal, citation metrics, Web of Science, pharmaceutical investigation, journal ranking, scholarly publishing